SynthesisFrontiers in oncology2025
Radiofrequency ablation versus surgical resection in colorectal liver metastasis: insight from an umbrella review.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thermal ablation versus liver resection for small colorectal liver metastases (≤ 3 cm): a systematic review and meta-analysis of randomized and propensity score-matched studies.Surgical endoscopy · 2026Pooled it
- Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Metastases: Safety and Clinical Outcomes in a Single-Center Case Series.Journal of clinical medicine · 2026Article
- Explainable Boosting Machine Predicting Length of Stay After Liver Surgery in Patients with Colorectal Liver Metastases.Cancers · 2026Article
- Spatial Porosity as a Diagnostic Predictor of Conductivity Collapse in Patient-Specific Radiofrequency Ablation of Liver Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Synchronous Isolated Cystic Pancreatic Metastasis Arising From Primary Colorectal Cancer: A Rare Case Report.The American journal of case reports · 2026Article
- Conversion-intent definitive liver-directed therapy improves survival in liver-predominant metastatic colorectal cancer.American journal of cancer research · 2026Article
- Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.Oncology reviews · 2026Review
- Radiofrequency ablation for colorectal liver metastases: an evolving alternative or complement to resection?Hepatobiliary surgery and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Radiofrequency ablation (RFA) has emerged as a less invasive alternative to surgical liver resection (LR) for the treatment of colorectal liver metastasis (CRLM) in patients who are not candidates for surgery. This umbrella review aimed to compare the effectiveness of RFA and LR in managing CRLM by synthesizing evidence from multiple meta-analyses. Methods: We conducted a comprehensive search across Medline, Epistemonikos, Scopus, and the Cochrane Library, focusing on survival outcomes, disease-free survival, perioperative complications, and recurrence rates. Results: Eleven meta-analyses met the inclusion criteria. The results show that LR is superior to RFA in terms of overall survival and disease-free survival for resectable CRLM, although RFA demonstrated lower perioperative complications and mortality. In matched cohorts, the overall survival rates between RFA and LR were comparable. However, RFA was associated with higher intrahepatic recurrence. Discussion: This review highlights the continued importance of LR for resectable CRLM, while RFA remains a valuable option for non-resectable cases, particularly in patients with higher morbidity. Future studies should focus on more balanced cohort comparisons to better assess the efficacy of these treatments. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024497886, identifier (CRD42024497886).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.